Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julie Gralow

Medical Oncology Seattle, WA Medical Doctor

NPI 1144300146 CMS profile 188442

Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Seattle, WA 98109

Open in the dashboard

General payments

$22,854

21 records reported · program years 2019–2025

Research payments

$4,923

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,186 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Julie Gralow of Seattle, WA is reported in the CMS Open Payments database as having received $22,854 across 21 general payments and $4,923 in research payments paid to them. Separately, studies naming them as principal investigator received $3,186 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $76 1
2021 General $6,312 3
2021 Research $3,787 4
2020 General $16,383 13
2020 Research $1,136 2
2019 General $83 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julie Gralow
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Julie Gralow were reported at $76. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Julie Gralow Medical Oncology median Middle half National median
2019 $83 $968 $140–$6,658 $163
2020 $16,383 $747 $102–$5,891 $114
2021 $6,312 $430 $50–$4,098 $132
2022 $0 $812 $127–$4,907 $149
2023 $0 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $76 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $9,300 3 payments
  2. Seattle Genetics, Inc. $4,436 6 payments
  3. Roche Products Limited $3,035 3 payments
  4. Novartis Pharmaceuticals Corporation $1,894 2 payments
  5. AstraZeneca Pharmaceuticals LP $1,789 3 payments
  6. AstraZeneca UK Limited $1,370 1 payment
  7. Genentech USA, Inc. $990 1 payment
  8. Puma Biotechnology, Inc. $29 1 payment
  9. Gilead Sciences, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $22,248 10 payments
  2. Food and Beverage $319 9 payments
  3. Travel and Lodging $276 1 payment
  4. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. TECENTRIQ $12,300 4 payments
  2. PIQRAY $1,875 1 payment
  3. Kadcyla $1,025 3 payments
  4. NERLYNX $29 1 payment
  5. KISQALI $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $4,923 6 payments

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record